Clinical trials: Graves' Hyperthyroidism, active
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Graves Disease, Mental Fatigue
Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored euthyroidism in Graves' disease is an autoimmune complication.
- Trial name
- NCT06081439
- Where
- Sweden
- Volunteers
- 430 people
- Sponsor
- Vastra Gotaland Region
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Optic Neuropathy
- Trial name
- NCT07594912
- Testing
- Teprotumumab N01, Intravenous Methylprednisolone (IVMP)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Thyroid Autoimmune Disease, Hashimoto's Thyroiditis
Impact of Restrictive Diets on Inflammation and Quality of Life in Autoimmune Thyroiditis
The purpose of this clinical trial is to evaluate whether a dietary intervention can improve clinical and immunological outcomes in women with autoimmune thyroid disease (AITD), including Hashimoto's thyroiditis and Graves'…
- Conditions
- Thyroid Autoimmune Disease, Hashimoto's Thyroiditis, Graves Disease
- Trial name
- TAILOR (NCT07879690)
- Testing
- Gluten-free, casein-free, low-glycemic-index diet
- Where
- Andorra
- Volunteers
- 60 people
- Sponsor
- University of Barcelona
Graves' Disease, Graves Disease
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated.
- Trial name
- VitaliThy (NCT07570316)
- Testing
- Efgartigimod PH20 SC
- Where
- 35 sites in United States, Georgia and 1 more
- Volunteers
- 230 people
- Sponsor
- argenx
Graves Disease
The Impact of Person Centred Care (PCC) in Grave's Disease
Mental fatigue (MF) is prevalent after Graves' disease (GD), which is the most common form of hyperthyroidism. We have reported that 38% of patients, compared to 11% of control subjects, suffer from MF more than 1 year after…
- Trial name
- NCT06309316
- Testing
- Person-centred care (PCC)
- Where
- Sweden
- Volunteers
- 220 people
- Sponsor
- Vastra Gotaland Region
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Thyroid Eye Disease
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
- Trial name
- NCT06248619
- Testing
- Teprotumumab
- Where
- 38 sites in United States, Argentina and 9 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Graves Disease, Graves' Disease
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
The goal of this randomized pilot feasibility clinical trial is to determine the feasibility of implementing a protocol for a larger trial to assess the effects of high-dose vitamin D supplementation in pediatric patients (9-17…
- Conditions
- Graves Disease, Graves' Disease, Hyperthyroidism
- Trial name
- NCT07369063
- Testing
- Ergocalciferol 50,000 IU, Methimazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Hyperthyroidism, Autoimmune, Cardiovascular Abnormalities
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease.
- Conditions
- Hyperthyroidism, Autoimmune, Cardiovascular Abnormalities, Malignant Tumor
- Trial name
- NCT07400224
- Testing
- Al18F-NOTA-FAPI PET/CT(or PET/MRI)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Graves' Orbitopathy, Thyroid Eye Disease, TED
Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease
The aim of this observational study is to investigate why some people with newly diagnosed Graves' disease (GD) develop thyroid eye disease (TED), also known as Graves' orbitopathy, while others do not.
- Conditions
- Graves' Orbitopathy, Thyroid Eye Disease, TED, Graves' Disease
- Trial name
- SOGO (NCT07812194)
- Testing
- Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status
- Where
- Denmark
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Thyroid Diseases, Congenital Hypothyroidism
Prospective Evaluation of OptiThyDose
The aim of this multicentric, randomised, two-arms and single-blinded clinical trial is to prospectively evaluate OptiThyDose for Congenital hypothyroidism (CH) and Graves' disease (GD).
- Conditions
- Thyroid Diseases, Congenital Hypothyroidism, Graves Disease
- Trial name
- NCT06864351
- Testing
- OptiThyDose
- Where
- 7 sites in Armenia, France and 1 more
- Volunteers
- 150 people
- Sponsor
- University Children's Hospital Basel
Graves' Disease
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years…
- Trial name
- NCT06984627
- Testing
- Rilzabrutinib dose 1, Rilzabrutinib dose 2
- Where
- 24 sites in Argentina, Canada and 7 more
- Volunteers
- 30 people
- Sponsor
- Sanofi
Thyroid Eye Disease
Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED
This randomized controlled trial aims to compare the efficacy and safety of transconjunctival versus transcutaneous perilevator betamethasone injection in reducing upper eyelid retraction in patients with thyroid eye disease.
- Trial name
- NCT07866261
- Testing
- Betamethasone
- Volunteers
- 54 people
- Sponsor
- Assiut University
Graves' Disease
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants…
- Trial name
- NCT07286006
- Testing
- IMVT-1402
- Where
- 131 sites in United States, Australia and 9 more
- Volunteers
- 372 people
- Sponsor
- Immunovant Sciences GmbH
Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
- Trial name
- NCT06727604
- Testing
- IMVT-1402
- Where
- 134 sites in United States, Belgium and 8 more
- Volunteers
- 240 people
- Sponsor
- Immunovant Sciences GmbH
Graves Disease
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
Graves' disease is an autoimmune disease. The TSH receptor antibody(TRab) produced by B cells drives the production of thyroid hormone, which causes systemic disorders and thyroid eye disease.
- Trial name
- NCT07129642
- Testing
- Allogeneic CAR-T
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Shanghai Zhongshan Hospital
Graves' Orbitopathy, Graves' Disease
Microbiota and Immune SignatureS of Graves' Disease and Orbitopathy
Graves' disease (GD) is the commonest cause of hyperthyroidism, characterised by anti-thyrotropin receptor autoantibodies (TRAb) persistently stimulating the thyroid gland.
- Conditions
- Graves' Orbitopathy, Graves' Disease, Graves' Ophthalmopathy, Basedow Disease
- Trial name
- MISS:GO (NCT07870161)
- Testing
- Aspiration 0
- Where
- Italy
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Graves Orbitopathy, Hyperthyroidism
Development of a Non-Invasive Prognostic Test for Graves Orbitopathy
The aim of this research project is to develop a non-invasive, simple, robust, and sensitive prognostic test that can identify hyperthyroidism patients who are at risk of developing Graves' Orbitopathy.
- Trial name
- GoPro (NCT07472062)
- Testing
- Schirmer's test
- Where
- Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent